Pharmaron Beijing Co., Ltd.

Equities

300759

CNE100003JW4

Biotechnology & Medical Research

End-of-day quote Shenzhen S.E. Other stock markets 06:00:00 2024-07-14 pm EDT			5-day change	1st Jan Change
19.23 ^CNY	-2.44%		+3.67%	-33.64%

Jul. 04	Pharmaron Beijing Buys Back, Applies to Delist Convertible Bonds	MT
Jul. 02	Tranche Update on Pharmaron Beijing Co., Ltd.'s Equity Buyback Plan announced on April 25, 2024.	CI

Tranche Update on Pharmaron Beijing Co., Ltd.'s Equity Buyback Plan announced on April 25, 2024.

July 02, 2024 at 08:36 am EDT

From April 25, 2024 to June 30, 2024, the company has repurchased 6,916,163 shares, representing 0.39% for CNY 151.12 million. With this, the company has completed the repurchase of 6,916,163 shares, representing 0.39% for CNY 151.12 million under the buyback announced on April 25, 2024.

Latest news about Pharmaron Beijing Co., Ltd.

Pharmaron Beijing Buys Back, Applies to Delist Convertible Bonds	Jul. 04	MT
Tranche Update on Pharmaron Beijing Co., Ltd.'s Equity Buyback Plan announced on April 25, 2024.	Jul. 02	CI
Pharmaron Beijing's Unit Receives Initial Payment for Disposal of Stake in Proteologix	Jun. 25	MT
Johnson & Johnson completed the acquisition of Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	Jun. 20	CI
Pharmaron Beijing Co., Ltd. Announces Final Cash Dividend on A Shares for the Year 2023, Payable June 27, 2024	Jun. 20	CI
Pharmaron Beijing Redeems 1.92 Billion Yuan Convertible Bonds	Jun. 20	MT
Pharmaron Beijing Co., Ltd. Approves Final Dividend for the Financial Year Ended December 31, 2023, Payable on July 26, 2024	Jun. 06	CI
Pharmaron Beijing Unit to Sell Proteologix Stake to Johnson & Johnson	May. 20	MT
Johnson & Johnson entered into a definitive agreement to acquire Proteologix, Inc. from Pharmaron Beijing Co., Ltd and other shareholders for approximately $850 million.	May. 15	CI
Pharmaron Beijing's Profit Rises 17% in 2023	Apr. 30	MT
Nomura Adjusts Pharmaron’s Price Target to 31.41 Yuan From 36.68 Yuan, Keeps at Buy	Apr. 29	MT
Pharmaron Beijing Posts 34% Profit Drop in Q1 as Revenue Slips 2%	Apr. 26	MT
Nomura Adjusts Pharmaron Beijing Co's Price Target to HK$15.41 From HK$17.99, Keeps at Buy	Apr. 26	MT
Pharmaron Beijing To Repurchase Shares Worth Up To 300 Million Yuan; Shares Jump 8%	Apr. 26	MT
Pharmaron Beijing Co., Ltd. announces an Equity Buyback for CNY 300 million worth of its shares.	Apr. 25	CI
Pharmaron Beijing Co., Ltd. Announces Executive Changes	Apr. 25	CI
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	Apr. 25	CI
Pharmaron Beijing Co., Ltd. authorizes a Buyback Plan.	Apr. 24	CI
Pharmaron Partners Seven Firms to Float 2 Billion Yuan Fund	Apr. 08	MT
Pharmaron's 2023 Profit, Revenue Rise; Misses Estimates	Mar. 28	MT
Pharmaron Beijing Co., Ltd. Proposes Final Dividend for the Financial Year Ended December 31, 2023, Payable on 26 July 2024	Mar. 27	CI
Pharmaron Beijing Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
Nomura Adjusts Pharmaron Beijing’s Price Target to HK$17.99 From HK$30.92, Keeps at Buy	Mar. 06	MT
Pharmaron Beijing Sees Up to 14% Jump in 2023 Profit	Jan. 29	MT
Pharmaron Forecasts Up to 19% Rise in 2023 Attributable Profit	Jan. 29	MT

Chart Pharmaron Beijing Co., Ltd.

Duration

Period

More charts

Company Profile

Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows: - laboratory services (61.3%); - development and production of chemical processes and formulations (23.5%); - clinical research services (12.8%); - other (2.4%); Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).

Sector

Biotechnology & Medical Research

Calendar

2024-08-27 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Ratings for Pharmaron Beijing Co., Ltd.

Trading Rating

Investor Rating

ESG Refinitiv

B+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

19.23 CNY

Average target price

22.71 CNY

Spread / Average Target

+18.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
PHARMARON BEIJING CO., LTD.	-33.64%	4.36B
MODERNA, INC.	+22.15%	46.55B
LONZA GROUP AG	+45.94%	41.84B
IQVIA HOLDINGS INC.	-2.37%	40.84B
ALNYLAM PHARMACEUTICALS, INC.	+33.84%	32.95B
CELLTRION, INC.	-6.35%	28.27B
ICON PUBLIC LIMITED COMPANY	+20.42%	27.78B
UNITED THERAPEUTICS CORPORATION	+48.83%	14.26B
MEDPACE HOLDINGS, INC.	+45.00%	13.69B
BIO-TECHNE CORPORATION	+0.06%	12.18B

Other Biotechnology & Medical Research